Marc C. Chamberlain
YOU?
Author Swipe
View article: Modeling human phenotypes in the nematode C. elegans during an undergraduate developmental biology course
Modeling human phenotypes in the nematode C. elegans during an undergraduate developmental biology course Open
Caenorhabditis elegans is a widely used model organism in biomedical research due to its genetic tractability, short life cycle, and conservation of many developmental processes with humans. In this study, undergraduate students conducted …
View article: Modeling human phenotypes in the nematode <i>C. elegans</i> during an undergraduate developmental biology course
Modeling human phenotypes in the nematode <i>C. elegans</i> during an undergraduate developmental biology course Open
Caenorhabditis elegans is a widely used model organism in biomedical research due to its genetic tractability, short life cycle, and conservation of many developmental processes with humans. In this study, undergraduate students conducted …
View article: Myeloid targeting antibodies PY159 and PY314 for platinum-resistant ovarian cancer
Myeloid targeting antibodies PY159 and PY314 for platinum-resistant ovarian cancer Open
Background Novel treatment options are required in patients with platinum-resistant ovarian cancer (PROC). Myeloid-derived suppressor cells promote a hostile tumor microenvironment and are associated with worse clinical outcomes in PROC. W…
View article: Phase 1b/2 study of orally administered pexidartinib in combination with radiation therapy and temozolomide in patients with newly diagnosed glioblastoma
Phase 1b/2 study of orally administered pexidartinib in combination with radiation therapy and temozolomide in patients with newly diagnosed glioblastoma Open
Background Glioblastoma (GBM) has a median survival of <2 years. Pexidartinib (PLX3397) is a small-molecule inhibitor of CSF1R, KIT, and oncogenic FTL3, which are implicated in GBM treatment resistance. Results from glioma models indica…
View article: Phase II trial of blood–brain barrier permeable peptide-paclitaxel conjugate ANG1005 in patients with recurrent high-grade glioma
Phase II trial of blood–brain barrier permeable peptide-paclitaxel conjugate ANG1005 in patients with recurrent high-grade glioma Open
Background This study is a phase II clinical trial to evaluate the efficacy, safety, and tolerability of the blood–brain barrier (BBB) permeable peptide-paclitaxel conjugate ANG1005 in patients with recurrent high-grade glioma (HGG) (NCT01…
View article: 126P Evaluation of myeloid targeting agents, PY159 and PY314, in two dose expansion phase Ib trials in platinum-resistant ovarian cancer
126P Evaluation of myeloid targeting agents, PY159 and PY314, in two dose expansion phase Ib trials in platinum-resistant ovarian cancer Open
Novel treatment options are required in patients with platinum-resistant ovarian cancer (PROC). Myeloid-derived suppressor cells facilitate a hostile tumor microenvironment and are associated with worse clinical outcomes in PROC. We evalua…
View article: Reviewer Lists
Reviewer Lists Open
Journal Article Reviewer Lists Get access Neuro-Oncology, Volume 25, Issue 1, January 2023, Pages 214–216, https://doi.org/10.1093/neuonc/noac277 Published: 05 January 2023 Article history Corrected and typeset: 05 January 2023 Published: …
View article: 1342 Therapeutic targeting of MARCO with PY265 antibody promotes myeloid cell reprogramming and unleashes anti-tumor immunity
1342 Therapeutic targeting of MARCO with PY265 antibody promotes myeloid cell reprogramming and unleashes anti-tumor immunity Open
Background The tumor microenvironment (TME) contains immunosuppressive myeloid cells that contribute to checkpoint inhibitor (CPI) resistance. One approach as part of Pionyr Immunotherapeutics' Myeloid Tuning™ strategy is to reprogram immu…
View article: A multi-institutional phase II trial of bevacizumab for recurrent and refractory meningioma
A multi-institutional phase II trial of bevacizumab for recurrent and refractory meningioma Open
Background Systemic therapies for refractory meningiomas are limited with no FDA-approved therapeutics. Vascular endothelial growth factor (VEGF) is a signaling protein associated with neovascularization, peritumoral edema, and meningioma …
View article: Leptomeningeal metastases: how best to assess response
Leptomeningeal metastases: how best to assess response Open
Leptomeningeal metastases (LM) is an uncommon complication of cancer where the overall incidence is <3% regardless of whether originating from a solid or a hematologic primary cancer.Less common still is the development of LM in primary br…
View article: A Bayesian adaptive randomized phase II multicenter trial of bevacizumab with or without vorinostat in adults with recurrent glioblastoma
A Bayesian adaptive randomized phase II multicenter trial of bevacizumab with or without vorinostat in adults with recurrent glioblastoma Open
Background Bevacizumab has promising activity against recurrent glioblastoma (GBM). However, acquired resistance to this agent results in tumor recurrence. We hypothesized that vorinostat, a histone deacetylase (HDAC) inhibitor with anti-a…
View article: PET imaging in patients with brain metastasis—report of the RANO/PET group
PET imaging in patients with brain metastasis—report of the RANO/PET group Open
Brain metastases (BM) from extracranial cancer are associated with significant morbidity and mortality. Effective local treatment options are stereotactic radiotherapy, including radiosurgery or fractionated external beam radiotherapy, and…
View article: ACTR-13. A BAYESIAN ADAPTIVE RANDOMIZED PHASE II TRIAL OF BEVACIZUMAB VERSUS BEVACIZUMAB PLUS VORINOSTAT IN ADULTS WITH RECURRENT GLIOBLASTOMA FINAL RESULTS
ACTR-13. A BAYESIAN ADAPTIVE RANDOMIZED PHASE II TRIAL OF BEVACIZUMAB VERSUS BEVACIZUMAB PLUS VORINOSTAT IN ADULTS WITH RECURRENT GLIOBLASTOMA FINAL RESULTS Open
Bevacizumab improves outcome and reduces symptoms in patients with recurrent glioblastoma (GBM). However, GBMs develop adaptive resistance to bevacizumab- mediated angiogenesis inhibition resulting in tumor recurrence. We hypothesized that…
View article: Tucatinib Combined With Ado-Trastuzumab Emtansine in Advanced <i>ERBB2/HER2</i>-Positive Metastatic Breast Cancer
Tucatinib Combined With Ado-Trastuzumab Emtansine in Advanced <i>ERBB2/HER2</i>-Positive Metastatic Breast Cancer Open
ClinicalTrials.gov Identifier: NCT01983501.
View article: Corticosteroid use endpoints in neuro-oncology: Response Assessment in Neuro-Oncology Working Group
Corticosteroid use endpoints in neuro-oncology: Response Assessment in Neuro-Oncology Working Group Open
This RANO proposal for corticosteroid use endpoints in neuro-oncology clinical trials may need to be refined and will require prospective validation in clinical studies.
View article: Volumetric response quantified using T1 subtraction predicts long-term survival benefit from cabozantinib monotherapy in recurrent glioblastoma
Volumetric response quantified using T1 subtraction predicts long-term survival benefit from cabozantinib monotherapy in recurrent glioblastoma Open
T1 subtraction maps provide value in determining response in recurrent GBM treated with cabozantinib and correlated with survival benefit.
View article: CMET-25. PROGRESSION-FREE SURVIVAL (PFS) AND SITE OF FIRST PROGRESSION IN HER2+ METASTATIC BREAST CANCER PATIENTS WITH OR WITHOUT BRAIN METASTASES: A POOLED ANALYSIS OF TUCATINIB PHASE I STUDIES
CMET-25. PROGRESSION-FREE SURVIVAL (PFS) AND SITE OF FIRST PROGRESSION IN HER2+ METASTATIC BREAST CANCER PATIENTS WITH OR WITHOUT BRAIN METASTASES: A POOLED ANALYSIS OF TUCATINIB PHASE I STUDIES Open
BACKGROUND: Brain metastases (BM) are frequent in HER2+ metastatic breast cancer (MBC) occurring in 50% of patients and are associated with significant neurologic morbidity and mortality. Tucatinib is a highly selective irreversible oral H…
View article: Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients with prior antiangiogenic therapy
Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients with prior antiangiogenic therapy Open
BackgroundCabozantinib is a potent, multitarget inhibitor of MET and vascular endothelial growth factor receptor 2 (VEGFR2). This open-label, phase II trial evaluated cabozantinib in patients with recurrent or progressive glioblastoma (GBM…
View article: Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients naive to antiangiogenic therapy
Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients naive to antiangiogenic therapy Open
NCT00704288 (https://www.clinicaltrials.gov/ct2/show/NCT00704288).
View article: Response assessment in medulloblastoma and leptomeningeal seeding tumors: recommendations from the Response Assessment in Pediatric Neuro-Oncology committee
Response assessment in medulloblastoma and leptomeningeal seeding tumors: recommendations from the Response Assessment in Pediatric Neuro-Oncology committee Open
Lack of standard response criteria in clinical trials for medulloblastoma and other seeding tumors complicates assessment of therapeutic efficacy and comparisons across studies. An international working group was established to develop con…
View article: The Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteria
The Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteria Open
The NANO scale provides an objective clinician-reported outcome of neurologic function with high inter-observer agreement. It is designed to combine with radiographic assessment to provide an overall assessment of outcome for neuro-oncolog…
View article: Cerebrospinal Fluid Dissemination and Neoplastic Meningitis in Primary Brain Tumors
Cerebrospinal Fluid Dissemination and Neoplastic Meningitis in Primary Brain Tumors Open
Neoplastic meningitis is a complicated disease in which response to therapy varies by histology. Thus, survival rates after CNS-directed therapy will differ by the underlying primary tumor. Optimal therapy of neoplastic meningitis is poorl…
View article: Neoplastic Meningitis Due to Lung, Breast, and Melanoma Metastases
Neoplastic Meningitis Due to Lung, Breast, and Melanoma Metastases Open
The prognosis of neoplastic meningitis remains poor. The increasing use of novel, targeted therapies and immunotherapy in solid tumors and its impact on neoplastic meningitis remains to be determined and is an area of active research. Thus…
View article: Systemic therapy of brain metastases: non–small cell lung cancer, breast cancer, and melanoma
Systemic therapy of brain metastases: non–small cell lung cancer, breast cancer, and melanoma Open
Brain metastases (BM) occur frequently in many cancers, particularly non-small cell lung cancer (NSCLC), breast cancer, and melanoma. The development of BM is associated with poor prognosis and has an adverse impact on survival and quality…